Australia's most trusted
source of pharma news
Posted 14 October 2024 AM
ASX-listed Chimeric Therapeutics has achieved a complete response in the first person enrolled to use its cell therapy as part of a combination treatment for Acute Myelogenous Leukemia (AML).
The Phase 1b trial is testing the natural killer cell therapy CHM CORE-NK in combination with oral TGF-β receptor inhibitor vactosertib in locally advanced or metastatic colorectal adenocarcinoma or relapsed or refractory haematologic malignancy. Participants have failed at least one standard line of chemotherapy, or they have either refused standard treatment regimens or there is no standard approach to curative salvage therapy.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.